Description: Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Location: Crestwood, KY
Year Invested: 2017
Status: Public (NASDAQ: APLS)
Website: www.apellis.comBack to Companies